• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arcellx, Inc. - Common Stock (NQ: ACLX )

    81.44 -2.07 (-2.48%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 421,761
    Open 82.24
    Bid (Size) 77.56 (1)
    Ask (Size) 84.82 (1)
    Prev. Close 83.51
    Today's Range 79.42 - 82.24
    52wk Range 30.88 - 88.66
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Assessing Arcellx: Insights From 7 Financial Analysts
    Via Benzinga
    ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
    ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +45.04%
    +45.04%
    1 Month
    +23.17%
    +23.17%
    3 Month
    +51.94%
    +51.94%
    6 Month
    +21.59%
    +21.59%
    1 Year
    +134.97%
    +134.97%

    More News

    Read More
    Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
    From Arcellx, Inc.
    Via Business Wire
    Decoding 8 Analyst Evaluations For Arcellx
    Via Benzinga
    FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
    Via InvestorPlace
    Exposures Product Safety
    Arcellx Stock Earns Relative Strength Rating Upgrade
    Via Investor's Business Daily
    The Latest Analyst Ratings For Arcellx
    Via Benzinga
    Expert Ratings For Arcellx
    Via Benzinga
    Analyst Expectations For Arcellx's Future
    Via Benzinga
    7 Biotech Stocks to Put on Your Breakthrough Radar
    Via InvestorPlace
    ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
    From Arcellx, Inc.
    Via Business Wire
    Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
    From Gilead Sciences, Inc.
    Via Business Wire
    Peering Into Arcellx's Recent Short Interest
    Via Benzinga
    Arcellx Analysts Boost Their Forecasts After Q4 Results
    Via Benzinga
    Arcellx Provides First Quarter 2024 Financial Results
    From Arcellx, Inc.
    Via Business Wire
    Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
    Via InvestorPlace
    Arcellx to Participate in Two Upcoming Investor Conferences
    From Arcellx, Inc.
    Via Business Wire
    Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Arcellx, Inc.
    Via Business Wire
    Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
    From Arcellx, Inc.
    Via Business Wire
    Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
    Via Benzinga
    The 3 Biotech Stocks That Could Make Your February Unforgettable
    Via InvestorPlace
    Decoding Bearish Analog And The Warning Signs You Can't Ignore
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
    Via InvestorPlace
    Exposures Product Safety
    Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.